1. Home
  2. KYMR vs MRCY Comparison

KYMR vs MRCY Comparison

Compare KYMR & MRCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • MRCY
  • Stock Information
  • Founded
  • KYMR 2015
  • MRCY 1981
  • Country
  • KYMR United States
  • MRCY United States
  • Employees
  • KYMR N/A
  • MRCY N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • MRCY
  • Sector
  • KYMR Health Care
  • MRCY
  • Exchange
  • KYMR Nasdaq
  • MRCY Nasdaq
  • Market Cap
  • KYMR 3.1B
  • MRCY 2.8B
  • IPO Year
  • KYMR 2020
  • MRCY 1998
  • Fundamental
  • Price
  • KYMR $42.63
  • MRCY $66.70
  • Analyst Decision
  • KYMR Strong Buy
  • MRCY Buy
  • Analyst Count
  • KYMR 16
  • MRCY 8
  • Target Price
  • KYMR $58.94
  • MRCY $59.13
  • AVG Volume (30 Days)
  • KYMR 622.1K
  • MRCY 768.9K
  • Earning Date
  • KYMR 08-11-2025
  • MRCY 08-11-2025
  • Dividend Yield
  • KYMR N/A
  • MRCY N/A
  • EPS Growth
  • KYMR N/A
  • MRCY N/A
  • EPS
  • KYMR N/A
  • MRCY N/A
  • Revenue
  • KYMR $44,711,000.00
  • MRCY $912,020,000.00
  • Revenue This Year
  • KYMR $58.26
  • MRCY $4.98
  • Revenue Next Year
  • KYMR N/A
  • MRCY $6.95
  • P/E Ratio
  • KYMR N/A
  • MRCY N/A
  • Revenue Growth
  • KYMR N/A
  • MRCY 9.19
  • 52 Week Low
  • KYMR $19.45
  • MRCY $32.32
  • 52 Week High
  • KYMR $53.27
  • MRCY $69.95
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 49.94
  • MRCY 75.98
  • Support Level
  • KYMR $36.65
  • MRCY $65.66
  • Resistance Level
  • KYMR $44.94
  • MRCY $69.95
  • Average True Range (ATR)
  • KYMR 1.64
  • MRCY 2.63
  • MACD
  • KYMR -0.18
  • MRCY 1.63
  • Stochastic Oscillator
  • KYMR 72.14
  • MRCY 83.60

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.

About MRCY Mercury Systems Inc

Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.

Share on Social Networks: